Potter Clarkson and ERS Genomics to affix forces with eureKARE on the eureKAWARDS
Potter Clarkson to supply the winner a Okayick-StartiP consultancy
ERS Genomics to supply essentially the most promising CRISPR/Cas9 staff with a complimentary three-year CRISPR/Cas9 license
Luxembourg and Paris, France – 14 September 2021: eureKARE (“the Firm”), a pioneering new firm centered on financing and constructing subsequent era biotechnology firms within the disruptive fields of the microbiome and artificial biology, right now proclaims it has secured the help of Potter Clarkson, an mental property legislation agency, and ERS Genomics, the worldwide CRISPR/Cas9 licensing chief, on the eureKAWARDS.
Supporting the event of artificial biology, the primary version of the eureKAWARDS is a global competitors designed with the purpose to find and determine essentially the most promising artificial biology initiatives and analysis throughout Europe. Along with eureKARE, each Potter Clarkson and ERS Genomics will likely be providing invaluable providers to eureKAWARDS semi-finalists and the successful entry.
Potter Clarkson will likely be offering IP schooling to all eureKAWARDS semi-finalists, in addition to one-to-one IP consultancy classes for all finalists. Potter Clarkson will likely be awarding the winner with its Kick-BeginiP consultancy, which is designed to assist companies perceive, determine, develop and doc their IP methods to start out a enterprise in the very best approach.
ERS Genomics will likely be providing a three-year license to essentially the most promising CRISPR/Cas9 submission on the eureKAWARDS. This gives broad entry to the foundational CRISPR/Cas9 mental property held by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner. As well as, ERS will present pitch coaching and mentoring to all semi-finalists.
Rodolphe Besserve, Chief Government Officer of eureKARE, mentioned: “We’re thrilled to be working with Potter Clarkson and ERS Genomics, each specialists of their fields. For members, it is a distinctive alternative to achieve entry to our skilled community of companions to achieve actual trade recommendation and insights on their enterprise concepts and initiatives.”
Sara Holland, patent lawyer specializing in artificial biology and biotechnology at Potter Clarkson, commented: “The analysis that’s being performed at universities throughout Europe has the potential to have a large influence on the world and assist remedy many international challenges, but it surely gained’t have that influence if it stays between the pages of an instructional journal.
“Naturally, nearly all of teachers don’t suppose notably commercially and infrequently don’t see the potential their analysis has, and so most of this potential isn’t realized. The professional-active strategy taken by eureKARE, whereby essentially the most thrilling analysis in educational labs within the artificial biology and microbiome house is recognized and commercialized, is each obligatory and impressed. Artificial biology is such an thrilling house to be in, and our staff really feel privileged to have the deep scientific technical backgrounds obligatory to know this rising space of deep tech and assist start-ups and spin-outs drag educational analysis out into the world.”
Eric Rhodes, Chief Executive Officer, ERS Genomics, added: “We’re within the enterprise of innovation. At ERS, we consider CRISPR/Cas9 will assist ship a greater, extra sustainable future for us and our planet. Already, use of CRISPR/Cas9 has offered options to beforehand insurmountable international points. Throughout a number of life science disciplines, together with agriculture, infectious illness and therapeutics, precision gene-editing is altering every part. Our imaginative and prescient is to allow an acceleration of life science breakthroughs by entry to our patent portfolio. The eureKAWARDS are in good concord with our targets. We need to see start-ups succeed, and we would like new concepts dropped at fruition. Working with eureKARE, we are going to play an lively position in encouraging innovation in Life Science.”
To be a part of the primary annual eureKAWARDS, please go to eurekare.eu/eurekawards for additional info on easy methods to submit your utility. The appliance portal will stay open till 10 October 2021.
– Finish –
eureKARE is a singular mission improvement firm devoted to investing and creating subsequent era biotechnology firms within the cutting-edge fields of the microbiome and artificial biology. eureKARE has a two-step funding strategy to ship long-term worth creation. The Firm helps translational analysis by creating and financing new firms out of excessive worth European science by its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Artificial biology). The Firm additionally intends to spend money on extra mature biotech firms and can systematically suggest to supply some liquidity to early buyers, thereby addressing a important want within the European biotech discipline. Guided by its influential founder, Alexandre Mouradian, and a pan-European staff, eureKARE has a quickly rising portfolio of firms which have the potential to disrupt the life sciences trade.
About Potter Clarkson
We assist firms, organisations and people throughout all sectors of enterprise to know, create, shield and defend the industrial worth of their improvements wherever on this planet by mental property rights. As a full-service mental property legislation agency with experience in patents, commerce marks, designs, litigation, licensing and consultancy, we will offer you specialist help in all areas of IP. For added info please go to https://www.potterclarkson.com
About ERS Genomics
ERS Genomics is a biotechnology firm primarily based in Dublin, Eire. The corporate gives broad entry to the foundational CRISPR/Cas9 mental property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses can be found for analysis and sale of services and products throughout a number of fields together with: analysis instruments, kits, reagents; discovery of novel targets for therapeutic intervention; cell traces for discovery and screening of novel drug candidates; GMP manufacturing of healthcare merchandise; companion animal and livestock well being; manufacturing of business supplies reminiscent of enzymes, biofuels and chemical substances; and artificial biology. For added info please go to www.ersgenomics.com
For extra info
Marina Shapochnik, Head Investor Relations